Goldman Sachs stock drops nearly 3% as Intel rout hits risk mood; GS investors eye Fed next week
23 January 2026
1 min read

Goldman Sachs stock drops nearly 3% as Intel rout hits risk mood; GS investors eye Fed next week

New York, January 23, 2026, 11:52 (EST) — Regular session.

Shares of The Goldman Sachs Group Inc (GS) dropped 2.9%, slipping $27.38 to $927.27 in late-morning trading on Friday.

U.S. stocks stumbled, dragged down by Intel’s steep drop after issuing a gloomy forecast. Concerns over tariffs linked to Greenland added to the jittery mood. “Guidance now is more critical than ever,” said Peter Cardillo, chief market economist at Spartan Capital Securities. Investors are bracing for next week’s Federal Reserve decision alongside major earnings reports from Apple, Microsoft, and Tesla. 1

Goldman’s slide hit the Dow hard, given it’s a price-weighted index where pricey stocks pack more punch. MarketWatch calculated that Goldman and American Express combined knocked roughly 204 points off the Dow in early trading. 2

Off the trading floor, Goldman has been ramping up efforts to secure more fee-based revenue from alternatives. The Wall Street Journal reported the bank raised $2.8 billion for a fourth private-equity co-investment fund, with “Goldman Sachs [current and former] employees” contributing 10% of the capital, according to Michael Brandmeyer. Co-investing involves investors putting money directly into specific deals alongside buyout firms, rather than committing to a blind-pool fund. 3

Goldman Sachs is one of four banks in the running for senior roles on a possible SpaceX IPO, a source told Reuters. Also in consideration are Bank of America, JPMorgan Chase, and Morgan Stanley, though the list could shift depending on market conditions. 4

Goldman’s research team is making waves in commodities. The bank raised its gold price target for the end of 2026 to $5,400 an ounce, up from $4,900. This boost is fueled by private-sector buying and demand from emerging-market central banks. Spot gold reached $4,887.82 on Wednesday, according to Reuters. 5

The bank is still processing its latest results after reporting a fourth-quarter profit beat last week, driven by strong dealmaking and trading. It also expressed confidence in investment banking prospects for this year. 6

Goldman bulls face a real risk: a geopolitical flare-up or the Fed stepping back from rate-cut speculation could slam the brakes on underwriting activity and delay M&A deals. Usually, those pressures hit the stock price long before they show up on the income statement.

Traders are now eyeing the Fed’s January 27-28 meeting. The policy decision lands on Wednesday, January 28 at 2:00 p.m. ET, followed by Chair Jerome Powell’s remarks at 2:30 p.m. 7

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
UnitedHealth stock price today: UNH steadies near $355 after Obamacare rebate pledge, with earnings next week
Previous Story

UnitedHealth stock price today: UNH steadies near $355 after Obamacare rebate pledge, with earnings next week

Boeing stock slips as FAA puts MAX 7/10 pressure back on the company; export-deal tally jumps
Next Story

Boeing stock slips as FAA puts MAX 7/10 pressure back on the company; export-deal tally jumps

Go toTop